MENU ▼
Read by QxMD icon Read
search
OPEN IN READ APP
JOURNAL ARTICLE

Long-course preoperative chemoradiation vs. 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: Long-term results of the randomized Polish II study

B Ciseł, L Pietrzak, W Michalski, L Wyrwicz, A Rutkowski, E Kosakowska, A Cencelewicz, M Spałek, W Polkowski, M Jankiewicz, R Styliński, M Bębenek, B Kapturkiewicz, A Maciejczyk, J Sadowski, J Zygulska, W Zegarski, M Jankowski, M Las-Jankowska, Z Toczko, U Żelazowska-Omiotek, L Kępka, J Socha, E Wasilewska-Tesluk, W Markiewicz, J Kładny, A Majewski, W Kapuściński, R Suwiński, K Bujko
Annals of Oncology: Official Journal of the European Society for Medical Oncology 2019 June 13
31192355

BACKGROUND: This trial evaluated whether preoperative short-course radiotherapy and consolidation chemotherapy (CCT) were superior to chemoradiation in rectal cancers with clinical (c)T4 or fixed cT3. Previously, we reported early results showing no differences in the radical surgery rate (primary end-point). In the short-course/CCT group, we observed lower acute toxicity of preoperative treatment and better overall survival (OS). We updated results to determine whether the benefit in OS was sustained and to evaluate late complications.

PATIENTS AND METHODS: Patients with cT4 or fixed cT3 rectal cancer were randomized either to preoperative 5 × 5 Gy and three cycles of FOLFOX4 or to chemoradiation (50.4 Gy with bolus 5-Fu, leucovorin and oxaliplatin).

RESULTS: 515 patients were eligible for analysis, 261 in the short-course/CCT group and 254 in the chemoradiation group. The median follow-up was 7.0 years. The difference in OS was insignificant, HR = 0.90 (95% confidence interval [CI] 0.70-1.15), P = 0.38. However, the difference in early OS favouring short-course/CCT previously reported was observed again, being 9% at 3 years (95% CI 0.5%-17%). This difference disappeared later; at 8 years OS was 49% in both groups. There was no difference in disease-free survival, HR = 0.95 (95% CI 0.75-1.19), P = 0.65, at 8 years 43% vs. 41% in the short-course/CCT group vs. the chemoradiation group, respectively. The corresponding values for cumulative incidences of local failure and distant metastases did not differ and were HR = 1.08, 95% CI 0.70-1.23, P = 0.60, 35% vs. 32% and HR = 1.10, 95% CI 0.68-1.23, P = 0.54, 36% vs. 34%, respectively. The rate of late complications was similar (P = 0.66), grade 3+ being 11% vs. 9% in the short-course/CCT group vs. the chemoradiation group, respectively.

CONCLUSION: The superiority of preoperative short-course/CCT over chemoradiation was not demonstrated.

CLINICAL TRIAL NUMBER: The trial is registered as ClinicalTrials.gov number NCT00833131.

Comments

You need to log in or sign up for an account to be able to comment.

No comments yet, be the first to post one!

Related Papers

Available on the App Store

Available on the Play Store
Remove bar
Read by QxMD icon Read
31192355
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"